Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Fischer

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
F&S Reports|June 22, 2026
Spontaneous ovarian hyperstimulation syndrome with a previously undescribed gene mutation of the follicle-stimulating hormone receptor gene: a case reportAnne-Christin Loheit, Ekkehard Schleussner, Mike Fischer, et al.
Cancer Immunology, Immunotherapy : CII|June 22, 2011
Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activationEdit Kovalcsik, Katie Lowe, Mike Fischer, et al.
Cancers|April 13, 2024
Synergistic Effects of the RAR<i>alpha</i> Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 MutationMaximilian Fleischmann, Julia Bechwar, Diana Voigtländer, et al.
Leukemia Research|September 4, 2013
The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cellsUlf Schnetzke, Mike Fischer, Bärbel Spies-Weisshart, et al.
Cytometry. Part B, Clinical Cytometry|April 12, 2013
Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses trackUlf Schnetzke, Mike Fischer, Jochen J Frietsch, et al.
Cells|November 27, 2021
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor ResistanceMaximilian Fleischmann, Mike Fischer, Ulf Schnetzke, et al.
Haematologica|December 31, 2016
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemiaMike Fischer, Ulf Schnetzke, Bärbel Spies-Weisshart, et al.
Aging|November 26, 2018
Cell cycle-dependent and -independent telomere shortening accompanies murine brain agingQuratul Ain, Christian Schmeer, Diane Penndorf, et al.
Journal of Cancer Research and Clinical Oncology|December 25, 2012
The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cellsUlf Schnetzke, Mike Fischer, Anne-Kathrin Kuhn, et al.
Plos One|March 11, 2016
Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid LeukemiaMike Fischer, Baerbel Spies-Weisshart, Karin Schrenk, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
F&S Reports|June 22, 2026
Spontaneous ovarian hyperstimulation syndrome with a previously undescribed gene mutation of the follicle-stimulating hormone receptor gene: a case reportAnne-Christin Loheit, Ekkehard Schleussner, Mike Fischer, et al.
Cancer Immunology, Immunotherapy : CII|June 22, 2011
Poly(I:C)-induced tumour cell death leads to DC maturation and Th1 activationEdit Kovalcsik, Katie Lowe, Mike Fischer, et al.
Cancers|April 13, 2024
Synergistic Effects of the RAR<i>alpha</i> Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 MutationMaximilian Fleischmann, Julia Bechwar, Diana Voigtländer, et al.
Leukemia Research|September 4, 2013
The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cellsUlf Schnetzke, Mike Fischer, Bärbel Spies-Weisshart, et al.
Cytometry. Part B, Clinical Cytometry|April 12, 2013
Paradoxical MAPK-activation in response to treatment with tyrosine kinase inhibitors in CML: flow cytometry loses trackUlf Schnetzke, Mike Fischer, Jochen J Frietsch, et al.
Cells|November 27, 2021
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor ResistanceMaximilian Fleischmann, Mike Fischer, Ulf Schnetzke, et al.
Haematologica|December 31, 2016
Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemiaMike Fischer, Ulf Schnetzke, Bärbel Spies-Weisshart, et al.
Aging|November 26, 2018
Cell cycle-dependent and -independent telomere shortening accompanies murine brain agingQuratul Ain, Christian Schmeer, Diane Penndorf, et al.
Journal of Cancer Research and Clinical Oncology|December 25, 2012
The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cellsUlf Schnetzke, Mike Fischer, Anne-Kathrin Kuhn, et al.
Plos One|March 11, 2016
Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid LeukemiaMike Fischer, Baerbel Spies-Weisshart, Karin Schrenk, et al.
Pageof 2